GlassScriptPhysician profile
Alexandra Burns
NPI 1780347690
$8,716.22
in general payments reported to CMS, 2019-2025
33 companies · $2,590 in 2025
The $2,590 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2022: $1,846 · 2023: $1,693 · 2024: $2,457 · 2025: $2,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,625 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,624.72 |
| Education | $115.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,268.32 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,044.57 | 2021-2025 | Trulance, Xifaxan, Relistor |
| Janssen Biotech, INC. | $668.84 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $488.00 | 2021-2025 | Entyvio, Gattex |
| Ardelyx, INC. | $429.75 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $380.62 | 2022-2023 | |
| Qol Medical, LLC | $294.16 | 2022-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $244.96 | 2023-2025 | Omvoh |
| Madrigal Pharmaceuticals | $244.68 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $206.75 | 2022-2025 | Interstim |
| Braintree Laboratories, INC. | $181.99 | 2022-2025 | Suflave, Sutab |
| Aimmune Therapeutics, INC. | $144.36 | 2024-2025 | Zenpep, Vowst |
| Janssen Scientific Affairs, LLC | $133.68 | 2022 | |
| Genzyme Corporation | $120.62 | 2024-2025 | |
| Evoke Pharma, INC. | $111.73 | 2022-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $109.81 | 2021-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $87.41 | 2025 | Iqirvo |
| Daiichi Sankyo INC. | $79.30 | 2021-2024 | Injectafer |
| Pfizer INC. | $64.67 | 2025 | |
| Ferring Pharmaceuticals INC. | $56.69 | 2022-2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $52.80 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $46.16 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $40.78 | 2022-2023 | Ocaliva |
| Celltrion USA INC. | $36.10 | 2023-2025 | Yuflyma, Vegzelma |
| Celgene Corporation | $32.77 | 2023 | Zeposia |
| Novo Nordisk INC | $24.59 | 2025 | Wegovy |
| Shield Therapeutics INC | $22.34 | 2024 | |
| Gilead Sciences, INC. | $20.41 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.72 | 2023 | Cyltezo |
| Enterra Medical, INC. | $16.03 | 2025 | |
| Ethicon US, LLC | $14.74 | 2022 | |
| Lucid Diagnostics INC. | $14.51 | 2023 | |
| Organon LLC | $14.36 | 2025 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.